NATCO announces ANDA filing for generic olaparib tablets in US EP News Bureau Feb 13, 2023 Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer
DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast… EP News Bureau Aug 22, 2022 New data from Olympia phase-III trial suggest that Olaparib demonstrated a statistically significant and clinically meaningful…
EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative… EP News Bureau Aug 5, 2022 It is the first and only approved medicine targetting BRCA mutations in early breast cancer
Merck to stop Keylynk-010 trial evaluating Keytruda in combination with Lynparza EP News Bureau Mar 16, 2022 In an interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in the overall survival, one of the…
LYNPARZA (olaparib) get three new approvals in Japan EP News Bureau Dec 29, 2020 Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials
AstraZeneca gets DCGI nod to import and market Olaparib film coated tablets EP News Bureau Aug 19, 2020 It is additionally indicated as a monotherapy to treat adults with metastatic castration-resistant prostate cancer and homologous…
AstraZeneca-Merck’s Lynparza wins approval in China for ovarian cancer treatment, Reuters Dec 5, 2019 The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or…
AstraZeneca’s Tagrisso helps lung cancer patients live longer: study Reuters Aug 9, 2019 The British drugmaker announced overall positive survival results from the study in patients with epidermal growth factor…